NAV Per Share Rebounds 13% to 110.4p
IP Group PLC reported a significant recovery in its 2025 financial year, with its net asset value (NAV) per share climbing 13% to 110.4 pence. According to its March 17, 2026, announcement, the university spinout investor's total NAV grew to £975.1 million. This performance marks a decisive turnaround from a challenging 2024, when the firm's NAV per share had declined by 15% and it recorded a loss of £207 million.
Pfizer's Metsera Deal Validates Biotech Strategy
The primary driver for the financial improvement was Pfizer’s acquisition of Metsera, an obesity drug developer held within IP Group's portfolio. This successful exit provided a substantial valuation uplift, underscoring the potential of IP Group's model of commercializing intellectual property from university research. The transaction highlights the high value placed on innovative biotech assets, particularly in high-demand fields like obesity treatment, and validates the firm's long-term investment strategy in the sector.
Strong Exit Signals Future Portfolio Value
The Metsera sale provides a clear positive signal to investors about the underlying value of other companies within IP Group's portfolio. By demonstrating a successful pathway from spinout to a major pharmaceutical acquisition, the firm has bolstered confidence in its ability to identify and scale high-growth ventures. This performance is likely to attract investor attention to the valuation of its other deep-tech and life science holdings, which could support the company's share price as the market reassesses its growth prospects.
Edgen Stock·Mar 17 2026, 08:21
